Marfan syndrome: from molecular pathogenesis to clinical treatment

Curr Opin Genet Dev. 2007 Jun;17(3):252-8. doi: 10.1016/j.gde.2007.04.006. Epub 2007 Apr 27.

Abstract

Marfan syndrome is a connective tissue disorder with ocular, musculoskeletal and cardiovascular manifestations that are caused by mutations in fibrillin-1, the major constituent of extracellular microfibrils. Mouse models of Marfan syndrome have revealed that fibrillin-1 mutations perturb local TGFbeta signaling, in addition to impairing tissue integrity. This discovery has led to the identification of a new syndrome with overlapping Marfan syndrome-like manifestations that is caused by mutations in TGFbeta receptor types I and II. It has also prompted the idea that TGFbeta antagonism will be a productive treatment strategy in Marfan syndrome and perhaps in other related disorders. More generally, these studies have established that Marfan syndrome is part of a group of developmental disorders with broad and complex effects on morphogenesis, homeostasis and organ function.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Connective Tissue / metabolism
  • Connective Tissue / pathology
  • Gene Expression Regulation
  • Humans
  • Marfan Syndrome / genetics
  • Marfan Syndrome / metabolism*
  • Marfan Syndrome / pathology*
  • Marfan Syndrome / therapy
  • Microfilament Proteins / genetics
  • Microfilament Proteins / metabolism
  • Signal Transduction
  • Transforming Growth Factor beta / metabolism

Substances

  • Microfilament Proteins
  • Transforming Growth Factor beta